Should I buy Corteva (CTVA) stock or is it too late?

Corteva · Materials · price $13

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 63% of its targets hit on this sector (185 calls tested). It aims for $15 (+12 %), call made on October 13, 2026, maturing on October 13, 2027 (1 d ago).

The 6 reliable analysts $14.63+9.5 %

The 7 other firms $14.25+6.7 %

How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $14.63 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Corteva

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Argus Research	80 %	+18.4 %	5	$14 +2%
Keybanc	83 %	+17.9 %	24	$17 +27%
UBS	91 %	+17.1 %	11	$15 +12%
Oppenheimer	100 %	+16.7 %	8	$14 +7%
RBC Capital	71 %	+15.8 %	14	$15 +16%
Morgan Stanley	78 %	+13.3 %	9	$14 +7%
Citigroup	69 %	+9.6 %	13	$14 +2%
BMO Capital	71 %	+8.1 %	7	$14 +7%

In short — Should you invest in Corteva? Is it too late, still worth it? Analysts are overwhelmingly positive (85% buy, median target $14, i.e. +7%), and the most reliable on CTVA targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

85% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
The most reliable firm on CTVA, Oppenheimer (100% hit rate, 8 scored calls), targets $14 (call made on July 23, 2026, maturing on July 23, 2027) (+7%) in its most recent call, and $12 (call made on January 27, 2026, maturing on January 27, 2027) (-12%) in the one coming due soonest.
Reasonable valuation (P/E ~8) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 2 are neutral.
Limited upside: the median target is only +7% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CTVA

Median target $14 (+7%) · 13 ratings · Buy consensus

Strong Buy00%

Buy1185%

Hold215%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Corteva now?

We won't decide for you. The facts: 85% of analysts rate it a buy, median target $14 (+7%), and Oppenheimer (most reliable on CTVA, 100%) targets $14. Weigh that against valuation (P/E ~8). This is not personalized advice.

Is it too late to invest in Corteva?

Not according to analysts: the median target ($14) is still +7% above the current price ($13) (most reliable on CTVA: Oppenheimer, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Corteva still worth investing in?

It depends on the gap between the price ($13) and its estimated value: analysts target $14 on median (+7%), with 85% buys (most reliable on CTVA: Oppenheimer, 100%). Cross-check with their real reliability on CTVA and the cautions above. Information, not advice.

What's the main risk in buying CTVA?

The consensus is not unanimous: of 13 ratings, 2 are neutral.

→ Go deeper: the full Corteva profile (consensus, analyst reliability, price target, performance).